Contact your healthcare provider if you experience: Severe or persistent abdominal pain Constipation lasting longer than two weeks despite dietary changes Vomiting or persistent nausea alongside constipation Complete inability to pass stool for several days Blood in stool or unexplained rectal bleeding These symptoms may indicate a more serious issue unrelated to GLP-1 medications and should always be evaluated by a qualified healthcare professional
More Medicare/Medicaid: A recurring $50 monthly charge on top of existing prescription spending represents a meaningful burden for that group, and because it sits outside Part D's benefit architecture, it does not bring them closer to the annual cap that shields against catastrophic drug costs
Image Credit: Love Employee / Shutterstock In a recent review published in The Journal of Clinical Investigation , researchers summarized current clinical evidence and relevant preclinical studies to assess the connection between glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and cancer outcomes
Two pharmaceutical company trials using longer-acting GLP-1 receptor agonists did not show the same disparity between carriers and non-carriers
The American College of Sports Medicine and U.S
"So that should be the emphasis of discussion when we are treating a patient for the disease of obesity." Listen to the full Cincinnati Edition interview on 91.7 WVXU News
